This is an excerpt from the original initial Phase IIb AIPAC results way back in March 25, 2020.
"AIPAC Principal Investigator, Hans Wildiers of University Hospitals Leuven, Leuven, Belgium, said: “I am
pleased to see this innovative chemo-immunotherapy approach in AIPAC is well tolerated by patients, while
showing a numerically (non-significant) higher progression free survival rate compared to chemotherapy
alone."
Which I guess speaks to the statistical significance of these results...
This is an excerpt from the original initial Phase IIb AIPAC...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
0.035(8.05%) |
Mkt cap ! $558.7M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 48.5¢ | 44.5¢ | $2.743M | 5.852M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 55686 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 39074 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
46.5¢ |
Change
0.035 ( 6.90 %) |
||||
| Open | High | Low | Volume | ||
| 45.0¢ | 48.5¢ | 45.0¢ | 1500168 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| IMM (ASX) Chart |